MAST Biosurgery USA never ran promised endotoxin tests on its SurgiWrap FROST surgical mesh and failed to report patient injuries, FDA says.
What happened
FDA inspected MAST Biosurgery USA's Irvine, CA facility from August 18 to August 21, 2025. Investigators found the firm had committed to FDA before clearance that it would test SurgiWrap FROST lots for endotoxins at or below 20 EU/device, but never did so before distributing the device in 2021. FDA also found complaints — including one reporting that 8 of 10 patients developed abdominal swelling — were reclassified as "feedback" and closed without investigation, and that required reports of serious patient injuries were never submitted to FDA.
What FDA found
The firm did not establish or follow procedures to prevent contamination of its implanted mesh, and never performed the endotoxin (bacterial toxin) testing on lots before release that it had promised FDA it would do.
21 CFR 820.70(e)Its complaint procedure allowed real complaints to be labeled "feedback" and closed without investigation, so a report that 8 of 10 patients developed abdominal swelling left no record of the nature or investigation of those events.
21 CFR 820.198(a)The firm did not send FDA required reports of serious injuries within 30 calendar days, and the report numbers it cited in its records were never received by FDA.
21 CFR 803.50(a)(1) and 803.12(a)
What FDA wants
FDA tells the firm to reply in writing within 15 business days of receiving the letter with the specific steps taken, documentation of corrections and corrective actions that address the systemic problems, and a timetable for anything that will take longer. FDA also states that a follow-up inspection will be required.
Who should pay attention
- hospitals and surgeons that implant SurgiWrap FROST mesh
- distributors and brands that resell MAST Biosurgery devices
- quality teams at other implantable-device makers that handle complaints and injury reports
This is a summary. Read the original letter on fda.gov.